{
    "nctId": "NCT00498901",
    "briefTitle": "Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer",
    "officialTitle": "Phase II Pilot of Aromatase Inhibitor Therapy With Femara\u00ae (Letrozole) and Ovarian Suppression in Premenopausal Estrogen Receptor Positive Women With Stage IV Carcinoma of the Breast",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1,
    "primaryOutcomeMeasure": "Overall response rate as measured by RECIST",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed carcinoma of the breast\n\n  * Metastatic disease\n* Measurable disease (i.e., unidimensional by RECIST)\n* No rapidly progressing visceral involvement (e.g., liver or lymphangitic lung disease)\n* No known marrow involvement as evidenced by diffuse uptake by imaging studies or bone marrow biopsy or aspirate\n* No evidence of CNS metastases\n* Estrogen- and/or progesterone-receptor positive status confirmed in primary breast tumor or in recent biopsy of metastatic site\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Premenopausal\\*, as defined by the following criteria:\n\n  * Less than 12 months from last menstrual period or premenopausal estradiol within the past 12 months\n  * No prior bilateral oophorectomy\n  * 45 years old or younger with intact ovaries and not a candidate for aromatase inhibitor therapy alone due to the potential for recurrent ovarian function NOTE: \\*Women are considered premenopausal after prior hysterectomy if they have intact ovaries and follicular hormone levels consistent with the institutional normal values for the premenopausal state\n* Women meeting premenopausal criteria prior to receiving ovarian suppression are eligible\n* ECOG performance status 0-2\n* Life expectancy \u2265 3 months\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective nonhormonal contraception during and for 12 weeks after discontinuation of study therapy\n* ANC \u2265 500 cells/mm\u00b3\n* Platelet count \u2265 50,000 cells/mm\u00b3\n* Hematocrit \u2265 28%\n* In the absence of liver metastases:\n\n  * AST and ALT \u2264 2.5 times upper limit of normal (ULN)\n  * Alkaline phosphatase \u2264 2.5 times ULN\n* In the presence of liver metastases:\n\n  * AST and ALT \u2264 5 times ULN\n  * Alkaline phosphatase \u2264 5 times ULN\n* In the presence of bone metastases:\n\n  * AST and ALT \u2264 10 times ULN\n  * Alkaline phosphatase \u2264 10 times ULN\n* Total bilirubin \u2264 2 times ULN\n* No significant comorbid conditions, including any of the following:\n\n  * Clinically significant cardiac disease not well controlled with medication (e.g., congestive heart failure, symptomatic coronary artery disease, or cardiac arrhythmias)\n  * Myocardial infarction within the past 12 months\n  * Serious concurrent infection\n* No lack of physical integrity of the upper gastrointestinal tract\n* No inability to swallow or malabsorption syndrome\n* No other carcinoma within the past 5 years except nonmelanoma skin cancer and treated in situ cervical cancer\n* No mental illness\n* No known hypersensitivity to luteinizing hormone-releasing hormone (LHRH), LHRH-agonist analogues, or any of the components in goserelin\n\nPRIOR CONCURRENT THERAPY:\n\n* No concurrent chemotherapy and/or additional hormonal therapy\n* Concurrent trastuzumab (Herceptin\u00ae) for patients with HER2 overexpression allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}